← All trials
NCT00049595
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2002
- Primary completion
- Jan 1, 2010
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 552
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- McMaster UniversityStudy chair
- CHU Henri MondorStudy chair
- Uppsala UniversityStudy chair
- Columbia UniversityStudy chair
- Australasian Leukaemia and Lymphoma GroupCollaborator
- Nordic Lymphoma GroupCollaborator
- Canadian Cancer Trials GroupCollaborator
- The Lymphoma Study AssociationCollaborator
- National Cancer Institute (NCI)Collaborator
- Grup per l'Estudi dels Limfomes de Catalunya i BalearsCollaborator
- Institut Gustave RoussyStudy chair
- University of BarcelonaStudy chair
- University of SydneyStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.